Global Incretin-Based Drugs Market was valued at USD 37.14 billion in 2023, and is anticipated to grow with a healthy growth rate of CAGR of 7.96% during the forecast period 2024-2032. Incretin-based drugs are a class of medications used to manage type 2 diabetes. These drugs mimic or enhance the effects of incretins, which are hormones that stimulate insulin release from the pancreas in response to meals. Through improving insulin secretion and reducing glucagon levels, incretin-based therapies help regulate blood sugar levels more effectively. Common types of incretin-based drugs include GLP-1 receptor agonists and DPP-4 inhibitors, both of which play a significant role in improving glycemic control and overall diabetes management.

The Global Incretin-Based Drugs Market is driven by rise in the prevalence of type 2 diabetes worldwide, coupled with an increase in the prescription of incretin-based drugs for its treatment, is driving the growth of the market. Incretin-based drugs have become essential in managing type 2 diabetes as they help regulate blood glucose levels by boosting insulin secretion and reducing glucagon release. This innovative approach to diabetes therapy addresses the escalating need for effective treatments in the face of a growing global diabetes population. The market's expansion is further fueled by significant investments in research and development of diabetes therapies that utilize incretin. Moreover, a strong pipeline of products and ongoing research are expected to drive the market forward over the forecast period. However, the market faces challenges such as side effects associated with excessive use and the high cost of incretin drugs, which may hinder widespread adoption.

The key regions considered for the Global Incretin-Based Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. In 2023, Asia-Pacific is poised to be the fastest-growing market for incretin-based drugs owing to rising healthcare expenditure and improving healthcare infrastructure. The increasing burden of chronic diseases including diabetes in this region underscores the demand for innovative and effective treatments, thereby expanding the market for incretin-based drugs. Furthermore, the market in North America is anticipated to dominate in terms of revenue over the forecast period 2024-2032.

Major market players included in this report are:
Sun Pharmaceutical Industries Ltd.
Lupin
Takeda Pharmaceutical Company Ltd.
AstraZeneca plc
Boehringer Ingelheim International GmbH
Eli Lilly and Company
Novartis AG
Novo Nordisk A/S
Merck & Co., Inc
Sanofi
The detailed segments and sub-segment of the market are explained below:
By Drug Class:
GLP-1 receptor agonists
DPP-4 inhibitors
By Route of Administration:
Oral
Parenteral
By Distribution Channel:
Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Providers
By Region:
North America:
U.S.
Canada
Europe:
UK
Germany
France
Spain
Italy
ROE
Asia Pacific:
China
India
Japan
Australia
South Korea
RoAPAC
Latin America:
Brazil
Mexico
Middle East & Africa:
Saudi Arabia
South Africa
RoMEA
Years considered for the study are as follows:
Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032
Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with country-level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market